Click on a transaction in order to view the corresponding press release.*
Current Investments
May 2025
Paratek
Total Facility: $275,000,000
Pharmakon Commitment: $50,000,000
Senior Secured Loan
Co-Lender
View Press Release
October 2024
Alphatec
Total Facility: $200,000,000
Pharmakon Commitment: $70,000,000
Senior Secured Loan
Co-Lender
View Press Release
March 2024
Urogen Pharma
$200,000,000
Senior Secured Loan
Sole Lender
December 2017
Bristol-Myers Squibb
$150,000,000
Structured Royalty Investment
Co-Investor
Realized Investments
February 2022
Collegium Pharmaceutical
$650,000,000
Senior Secured Loan
Sole Lender
March 2021
Lumira DX
$300,000,000
Senior Secured Loan
Sole Lender
February 2020
Collegium Pharmaceutical
$200,000,000
Senior Secured Loan
Sole Lender
View Press Release
December 2019
GBT
$250,000,000
Senior Secured Loan
Sole Lender
November 2019
Epizyme
$150,000,000
Senior Secured Loan
Sole Lender
May 2019
BioDelivery Sciences
$80,000,000
Senior Secured Loan
Sole Lender
May 2018
Sebela
$315,000,000
Senior Secured Loan
Lead
December 2017
Lexicon
$200,000,000
Senior Secured Loan
Sole Lender
November 2017
Tesaro
$500,000,000
Senior Secured Loan
Sole Lender
September 2017
Saol
$50,000,000
Corporate Loan
Sole Lender
November 2016
Vimpat
$Undisclosed
Capped Royalty
Sole Purchaser
January 2016
Halozyme
$150,000,000
Royalty Backed Loan
Lead
December 2015
Merrimack
$175,000,000
Corporate Loan
Sole Lender
November 2015
iRhythm
$55,000,000
Senior Secured Loan
Sole Lender
March 2015
Depomed
$575,000,000
Senior Secured Loan
Lead
January 2015
Novocure
$100,000,000
Senior Secured Loan
Sole Lender
December 2013
Valneva
$30,000,000
Senior Secured Loan
Sole Lender
December 2012
Vascepa
$100,000,000
Capped Royalty
Sole Purchaser
November 2012
Curis
$30,000,000
Senior Secured Loan
Sole Purchaser
August 2012
Korlym
$30,000,000
Capped Royalty
Sole Purchaser
August 2012
Xience Prime
$78,000,000
Capped Royalty
Sole Purchaser
May 2010
Cubicin
$100,000,000
Royalty Backed Notes
Sole Purchaser
September 2009
Cymbalta
$132,000,000
Royalty Backed Notes
Sole Purchaser
*Nothing in any referenced press release is intended to be, nor should be construed as, a testimonial or endorsement regarding Pharmakon as an investment advisors. No compensation has been provided to any executives providing statements regarding Pharmakon, but, due to Pharmakon’s client’s investments in the relevant issuers, any statements made regarding Pharmakon in the press release involve an inherent conflict of interest. To Pharmakon’s knowledge, none of the officers or directors of the borrowers quoted in the following are clients or investors in funds managed by Pharmakon.
Press Releases
Click on a press release to view it in a new window.*
May 2025
Paratek
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
Read moreMay 2025
Evolus
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
Read moreOctober 2024
Insmed
Insmed renegotiates Term Loan with Pharmakon Resulting in a Lower Cost of Capital and an Additional $150 Million in Proceeds to be Received in the Fourth Quarter
Read moreOctober 2024
Geron
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
Read moreOctober 2024
Alphatec
ATEC Spine, Inc. Reports Third Quarter 2024 Financial Results And Raises Full-Year Guidance
Read moreMay 2024
Novocure
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon – Novocure
Read moreApril 2024
Tarsus
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Read moreMay 2023
Reata
Pharmakon Advisors provides $275 Million Debt Facility to Reata Pharmaceuticals
Read moreApril 2023
BioCryst
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon
Read moreMarch 2022
Urogen
UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven
Read moreFebruary 2022
Collegium
Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio
Read moreDecember 2021
Evolus
Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors
Read moreDecember 2019
Serepta
Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing
Read moreNovember 2019
Akebia
Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results
Read moreSeptember 2018
Amicus
Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders
Read moreApril 2017
BioPharma Credit PLC
BioPharma Credit PLC US$ 762 million IPO and admission to trading on the London Stock Exchange, bringing total capital raised by Pharmakon funds to US$ 2.4 billion
Read moreJanuary 2015
Novocure
Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors
Read moreMarch 2015
Depomed
Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® Acquisition
Read moreJanuary 2015
Novocure
Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors
Read moreAugust 2012
Corcept
Corcept Therapeutics Announces $30 Million Synthetic, Capped Royalty Transaction; Terminates Committed Equity Financing Facility
Read more*Nothing in any referenced press release is intended to be, nor should be construed as, a testimonial or endorsement regarding Pharmakon as an investment advisors. No compensation has been provided to any executives providing statements regarding Pharmakon, but, due to Pharmakon’s client’s investments in the relevant issuers, any statements made regarding Pharmakon in the press release involve an inherent conflict of interest. To Pharmakon’s knowledge, none of the officers or directors of the borrowers quoted in the following are clients or investors in funds managed by Pharmakon.
